Global Anti-Nuclear Antibody Test Market- Industry Trends and Forecast to 2025

  • Pharmaceutical
  • Published Report
  • Feb 2018
  • Global
  • 248 Pages
  • No of Tables: 54
  • No of Figures: 153
Global Anti-nuclear Antibody Test Market Product (Assay Kits & Reagents, Systems, Software), Test (Indirect Immunofluorescence, ELISA, Multiplex Testing), Disease (Systemic Lupus Erythematosus, Sjögren’s Syndrome, Rheumatoid Arthritis, Scleroderma, Polymyositis), End-User (Hospitals, Clinics, Physician Office Laboratories), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)- Industry Trends and Forecast to 2025 Global Anti-Nuclear Antibody Test Market is expected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Global Anti-Nuclear Antibody Test MarketThe major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

Market Segmentation: Global Anti-Nuclear Antibody Test Market

  • The global anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the global anti-nuclear antibody test market with 56.4% market share and is expected to reach USD 1,122.30 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.
  • The global anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the anti-nuclear antibody test market with 53.3% market share and is expected to reach USD 998.35 million by 2025, with the CAGR of 7.0% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.0% in the forecast period, and is expected to reach USD 406.29 million in 2025 from USD 205.60 million in 2017.
  • The global anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the global antinuclear antibody test market with 37.6% market share and is expected to reach USD 766.06 million by 2025, at the highest CAGR of 8.3% in the forecast period 2018 to 2025.
  • The global anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the global antinuclear antibody test market with 53.4% market share and is expected to reach USD 1,062.43 million by 2025, at the highest CAGR of 7.9% in the forecast period 2018 to 2025.
  • Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa.

Key Drivers: Global Anti-Nuclear Antibody Test Market

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

On the other hand, strict regulation for product approval is hampering the growth of the market.

Key Points: Global Anti-Nuclear Antibody Test Market

In 2017, the global anti-nuclear antibody test market is dominated by Alere, Inc., followed by Bio-Rad Laboratories and ThermoFisher Scientific, Inc.

  • Assay Kits & Reagents is dominating the global anti-nuclear antibody test market.
  • North America is dominating the anti-nuclear antibody test market in the forecast period 2018 to 2025.

SKU-

TABLE OF CONTENTS GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY 1.2. MARKET DEFINITION 1.3. OVERVIEW OF GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET 1.4. CURRENCY AND PRICING 1.5. LIMITATION 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED 2.2. GEOGRAPHIC SCOPE 2.3. YEARS CONSIDERED FOR THE STUDY 2.4. CURRENCY AND PRICING 2.5. RESEARCH METHODOLOGY 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7. SECONDARY SOURCES 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES 3.1.2. RISING MEDICAL INSURANCE 3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION

3.2. RESTRAINTS

3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL

3.3. OPPORTUNITIES

3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE 3.3.2. EMERGING MARKETS 3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET

3.4. CHALLENGES

3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY 5. PREMIUM INSIGHTS 6. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

6.1. OVERVIEW 6.2. ASSAY KITS & REAGENTS 6.3. SYSTEMS 6.4. SOFTWARE

7. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

7.1. OVERVIEW 7.2. INDIRECT IMMUNOFLUORESCENCE 7.3. ELISA 7.4. MULTIPLEX TESTING

8. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

8.1. OVERVIEW 8.2. RHEUMATOID ARTHRITIS 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS 8.4. SJÖGREN’S SYNDROME 8.5. SCLERODERMA 8.6. POLYMYOSITIS 8.7. OTHERS

9. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

9.1. OVERVIEW 9.2. HOSPITALS 9.3. CLINICS 9.4. PHYSICIAN OFFICE LABORATORIES 9.5. OTHERS

10. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

10.1. OVERVIEW

10.2. NORTH AMERICA

10.2.1. U.S. 10.2.2. CANADA 10.2.3. MEXICO

10.3. EUROPE

10.3.1. GERMANY 10.3.2. FRANCE 10.3.3. U.K. 10.3.4. ITALY 10.3.5. SPAIN 10.3.6. SWITZERLAND 10.3.7. NETHERLANDS 10.3.8. BELGIUM 10.3.9. RUSSIA 10.3.10. TURKEY 10.3.11. REST OF EUROPE

10.4. ASIA-PACIFIC

10.4.1. CHINA 10.4.2. JAPAN 10.4.3. INDIA 10.4.4. SOUTH KOREA 10.4.5. AUSTRALIA 10.4.6. SINGAPORE 10.4.7. THAILAND 10.4.8. MALAYSIA 10.4.9. INDONESIA 10.4.10. PHILIPPINES 10.4.11. REST OF ASIA-PACIFIC

10.5. SOUTH AMERICA

10.5.1. BRAZIL 10.5.2. REST OF SOUTH AMERICA

10.6. MIDDLE EAST & AFRICA

10.6.1. SOUTH AFRICA 10.6.2. REST OF MIDDLE EAST & AFRICA

11. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, COMPANY LANDSCAPE 220

11.1. COMPANY SHARE ANALYSIS: GLOBAL 11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA 11.3. COMPANY SHARE ANALYSIS: EUROPE 11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

12.1. THERMO FISHER SCIENTIFIC INC.

12.1.1. COMPANY OVERVIEW 12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS 12.1.3. PRODUCT PORTFOLIO 12.1.4. RECENT DEVELOPMENTS

12.2. MERCK KGAA

12.2.1. COMPANY OVERVIEW 12.2.2. MERCK KGAA: REVENUE ANALYSIS 12.2.3. PRODUCT PORTFOLIO 12.2.4. RECENT DEVELOPMENTS

12.3. ALERE INC.

12.3.1. COMPANY OVERVIEW 12.3.2. ALERE INC.: REVENUE ANALYSIS 12.3.3. PRODUCT PORTFOLIO 12.3.4. RECENT DEVELOPMENTS

12.4. TRINITY BIOTECH

12.4.1. COMPANY OVERVIEW 12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW 12.4.3. PRODUCT PORTFOLIO 12.4.4. RECENT DEVELOPMENTS

12.5. ANTIBODIES INC.

12.5.1. COMPANY OVERVIEW

12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS 12.5.3. PRODUCT PORTFOLIO 12.5.4. RECENT DEVELOPMENTS

12.6. BIO-RAD LABORATORIES, INC.

12.6.1. COMPANY OVERVIEW 12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 12.6.3. PRODUCT PORTFOLIO 12.6.4. RECENT DEVELOPMENTS

12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)

12.7.1. COMPANY OVERVIEW 12.7.2. PERKINELMER INC.: REVENUE ANALYSIS 12.7.3. PRODUCT PORTFOLIO 12.7.4. RECENT DEVELOPMENTS

12.8. IMMUNO CONCEPTS

12.8.1. COMPANY OVERVIEW 12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT 12.8.3. PRODUCT PORTFOLIO 12.8.4. RECENT DEVELOPMENTS

12.9. INOVA DIAGNOSTICS

12.9.1. COMPANY OVERVIEW 12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT 12.9.3. PRODUCT PORTFOLIO 12.9.4. RECENT DEVELOPMENTS

12.10. ZEUS SCIENTIFIC, INC.

12.10.1. COMPANY OVERVIEW 12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT 12.10.3. PRODUCT PORTFOLIO 12.10.4. RECENT DEVELOPMENTS

12.11. MBL INTERNATIONAL

12.11.1. COMPANY OVERVIEW 12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT 12.11.3. PRODUCT PORTFOLIO 12.11.4. RECENT DEVELOPMENTS

12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD

12.12.1. COMPANY OVERVIEW 12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT 12.12.3. PRODUCT PORTFOLIO 12.12.4. RECENT DEVELOPMENTS

12.13. AESKU GROUP GMBH & CO. KG

12.13.1. COMPANY OVERVIEW 12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT 12.13.3. PRODUCT PORTFOLIO 12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

LIST OF TABLE GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET

TABLE 1 PREVALENCE OF FEW AUTOIMMUNE DISEASESIN U.S. (2012) TABLE 2 PROJECT FUNDING FOR RHEUMATOID ARTHRITIS AND LUPUS (2018-2023) (USD MILLION) TABLE 3 HEALTHCARE EXPENDITURE IN ASIA PACIFIC (USD MILLION) TABLE 4 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 5 GLOBAL ASSAY KITS & REAGENTS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 6 GLOBAL SYSTEMS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 7 GLOBAL SOFTWARES MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 8 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 9 GLOBAL INDIRECT IMMUNOFLUORESCENCE MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 10 GLOBAL ELISA MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 11 GLOBAL MULTIPLEX TESTING MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 12 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 13 GLOBAL RHEUMATOID ARTHRITIS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 14 GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 15 GLOBAL SJÖGREN’S SYNDROME MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 16 GLOBAL SCLERODERMA MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 17 GLOBAL POLYMYOSITIS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 18 GLOBAL OTHERS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 19 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 20 GLOBAL HOSPITALS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 21 GLOBAL CLINICS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 22 GLOBAL PHYSICIAN OFFICE LABORATORIES MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 23 GLOBAL OTHERS MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 24 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY REGION, 2016 – 2025 (USD MILLION) TABLE 25 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2016-2025 (USD MILLION) TABLE 26 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 27 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 28 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 29 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 30 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 31 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 32 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 33 U.S. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 34 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 35 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 36 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 37 CANADA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 38 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 39 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 40 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 41 MEXICO ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 42 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2016-2025 (USD MILLION) TABLE 43 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 44 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 45 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 46 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 47 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 48 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 49 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 50 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 51 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 52 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 53 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 54 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 55 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 56 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 57 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 58 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 59 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 60 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 61 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 62 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 63 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 64 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 65 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 66 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 67 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 68 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 69 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 70 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 71 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 72 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 73 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 74 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 75 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 76 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 77 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 78 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 79 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 80 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 81 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 82 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 83 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 84 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 85 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 86 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 87 REST OF EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 88 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2016-2025 (USD MILLION) TABLE 89 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 90 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 91 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 92 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 93 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 94 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 95 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 96 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 97 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 98 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 99 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 100 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 101 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 102 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 103 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 104 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 105 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 106 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 107 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 108 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 109 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 110 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 111 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 112 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 113 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 114 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 115 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 116 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 117 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 118 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 119 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 120 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 121 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 122 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 123 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 124 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 125 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 126 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 127 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 128 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 129 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 130 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 131 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 132 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 133 REST OF ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 134 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2016-2025 (USD MILLION) , TABLE 135 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 136 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 137 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 138 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 139 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 140 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 141 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 142 BRAZIL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 143 REST OF SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 144 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY, 2016-2025 (USD MILLION) , TABLE 145 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 146 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 147 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 148 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 149 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION) TABLE 150 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST, 2016 - 2025 (USD MILLION) TABLE 151 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE, 2016 - 2025 (USD MILLION) TABLE 152 SOUTH AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER, 2016 - 2025 (USD MILLION) TABLE 153 REST OF MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT, 2016 - 2025 (USD MILLION)

LIST OF FIGURES GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET

FIGURE 1 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: SEGMENTATION FIGURE 2 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: DATA TRIANGULATION FIGURE 3 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : RESEARCH SNAPSHOT FIGURE 4 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : BOTTOM UP APPROACH FIGURE 5 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: TOP DOWN APPROACH FIGURE 6 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : INTERVIEW DEMOGRAPHICS FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET FIGURE 8 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET : SEGMENTATION FIGURE 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR ANTI-NUCLEAR ANTIBODY TEST AND ASIA PACIFIC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2018 TO 2025 FIGURE 10 INCREASING INCIDENCE OF AUTOIMMUNE DISEASES, RISING MEDICAL INSURANCE ARE EXPECTED TO DRIVE THE MARKET FOR ANTI-NUCLEAR ANTIBODY TEST MARKET IN THE FORECAST PERIOD 2018 TO 2025 FIGURE 11 ASSAY KITS & REAGENTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET IN 2018 & 2025 FIGURE 12 ASIA PACIFIC IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR ANTI-NUCLEAR ANTIBODY TEST MANUFACTURERS IN THE FORECAST PERIOD FROM 2018 TO 2025 50 FIGURE 13 PREVALENCE OF RHEUMATOID ARTHRITIS IN FEW COUNTRIES (2015) FIGURE 14 PREVALENCE OF SYSTEMIC LUPUS ERYTHEMATOSUS IN FEW COUNTRIES (2015) FIGURE 15 PREVALENCE OF SJOGREN'S SYNDROME IN FEW COUNTRIES (2015) FIGURE 16 PREVALENCE OF SCLERODERMA IN FEW COUNTRIES (2015) FIGURE 17 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE, 2017 FIGURE 18 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY TEST, 2017 FIGURE 19 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY DISEASE, 2017 FIGURE 20 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY END USER, 2017 FIGURE 21 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET SNAPSHOT (2017) FIGURE 22 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2017) FIGURE 23 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2018) FIGURE 24 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017 & 2025) FIGURE 25 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE (2018 & 2025) FIGURE 26 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) FIGURE 27 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) FIGURE 28 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET : BY COUNTRY (2018 & 2025) FIGURE 29 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2018 & 2025) FIGURE 30 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) FIGURE 31 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) FIGURE 32 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) FIGURE 33 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET : BY COUNTRY (2018 & 2025) FIGURE 34 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) FIGURE 35 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) FIGURE 36 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) FIGURE 37 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) FIGURE 38 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET : BY COUNTRY (2018 & 2025) FIGURE 39 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) FIGURE 40 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) FIGURE 41 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) FIGURE 42 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) FIGURE 43 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET : BY COUNTRY (2018 & 2025) FIGURE 44 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) FIGURE 45 SOUTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) FIGURE 46 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) FIGURE 47 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) FIGURE 48 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET : BY COUNTRY (2018 & 2025) FIGURE 49 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) FIGURE 50 MIDDLE EAST & AFRICA ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) FIGURE 51 GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) FIGURE 52 NORTH AMERICA ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) FIGURE 53 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) FIGURE 54 ASIA PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART